CC-292

Known as: Bruton's Tyrosine Kinase Inhibitor CC-292 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2016
02420132016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
CC-292, a potent Bruton tyrosine kinase inhibitor, is under development for the treatment of B-cell malignancies. An analysis was… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2017
2017
Correlating target engagement with in vivo drug activity remains a central challenge in efforts to improve the efficiency of drug… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • table 1
Is this relevant?
Review
2017
Review
2017
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia… (More)
  • table 1
Is this relevant?
2016
2016
Additions of cysteine thiols to Michael acceptors underpin the mechanism of action of several covalent drugs (e.g., afatinib… (More)
Is this relevant?
2016
2016
inhibition suppresses B celland myeloid cell-mediated arthritis. Nat Chem Biol 2011; 7: 41–50. 14 Evans EK, Tester R, Aslanian S… (More)
  • figure 1
  • figure 2
Is this relevant?
2014
2014
Bruton’s tyrosine kinase (Btk) modulates B-cell development and activation and has an important role in antibody production… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2014
Review
2014
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. The current treatment paradigm involves the use of… (More)
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2013
2013
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B… (More)
Is this relevant?
2013
2013
Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?